A Phase 1, Randomized, Double Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KZR-616 in Healthy Subjects

Trial Profile

A Phase 1, Randomized, Double Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KZR-616 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs KZR 616 (Primary) ; KZR 616 (Primary)
  • Indications Autoimmune disorders
  • Focus Adverse reactions; First in man
  • Sponsors Kezar Life Sciences
  • Most Recent Events

    • 30 Aug 2017 Status changed from recruiting to completed.
    • 25 Jul 2017 According to a Kezar Life Sciences media release, additional results from the study are anticipated to be presented at the American College of Rheumatology's Annual Meeting in San Diego in November.
    • 25 Jul 2017 Results published in a Kezar Life Sciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top